LSPedia Unveils Serialized Recall Management Module at HDA 2025 Traceability Seminar

WASHINGTON, Aug. 5, 2025 /PRNewswire/ — LSPedia, the leader in pharmaceutical serialization and supply chain technology, announced its groundbreaking Serialized Recall Management Module at the Healthcare Distribution Alliance’s Annual Traceability Seminar. This launch marks a significant leap forward in pharmaceutical recall automation, value beyond serialization compliance, and improved patient safety.

Built on LSPedia’s OneScan® platform, the Serialized Recall Module transforms the way recalls are initiated, tracked, and resolved across the pharmaceutical supply chain. By tackling long-standing pain points—fragmented communication, manual workflows, regulatory complexity, and reputational risk—LSPedia is delivering a solution that’s fast, intelligent, and scalable. Customers can expect dramatically reduced recall notification time, up to 90% fewer manual labor hours, and end-to-end precision in recall execution.

“In the age of AI, there’s no reason drug recalls should still be mired in paperwork, confusion, and delay,” said Riya Cao, CEO of LSPedia. “We’ve eliminated the complexity of recalls. OneScan’s Serialized Recall Module is AI that works hard for you—it listens, acts, and resolves before risks escalate. This is how we create operational value and build trust across the pharma supply chain and with our patient communities.”

“Every pharmaceutical company today—if not already executing—is thinking seriously about their AI strategy,” Cao added. “Serialized Recall isn’t just built with AI—it enables AI at scale, powering a smarter, faster, and more resilient supply chain.”

Designed to maximize the utility of serialized data, the module empowers manufacturers, distributors, and dispensers to pinpoint affected products down to the lot and serial number, automatically notify impacted parties, and manage reconciliation in real time.

Key capabilities include:

  • Ambient Listening using AI/ML to detect recall triggers
  • Automated Recall Initiation integrated with EPCIS transactions
  • Targeted Notifications to distributions centers and downstream customers
  • End-to-End Reconciliation with location-level visibility
  • Integrated Return Logistics with labels, shipping, and decommissioning data exchange (Recall+)

The Serialized Recall Module is available to early adopters in August 2025, with general availability scheduled for October 2025. The enhanced Recall+ version—designed for end-to-end automation across OneScan Enterprise—will enter early access in Q1 2026.

“LSPedia’s Investigator is already the gold standard for exception management.” Said Adam Moy, CTO of LSPedia. “Our Serialized Recall Management Module is destined to become the gold standard for drug recall—an essential capability for a modern, digital, and intelligent pharmaceutical supply chain.”

This launch reinforces LSPedia’s leadership in serialized operations, digital transformation, and AI-driven compliance innovation—helping the pharmaceutical industry move faster, operate smarter, and serve patients better.

To request a demo or learn more, email trace@lspedia.com or visit www.lspedia.com.

Media Contact:
Eric Kushner
2489875856
399194@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lspedia-unveils-serialized-recall-management-module-at-hda-2025-traceability-seminar-302521390.html

SOURCE LSPedia

Staff

Recent Posts

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the…

5 hours ago

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope…

5 hours ago

Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the…

5 hours ago

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal…

5 hours ago

WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025

Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK)…

5 hours ago